FDANonrulemakingFDA-2021-D-0528

Who commented on this docket

Quantifying Sodium, Potassium, and Phosphorus in Labeling for Human Over-the-Counter and Prescription Drug Products; Draft Guidance for Industry; Availability

1 organizations filed 2 public comments on Quantifying Sodium, Potassium, and Phosphorus in Labeling for Human Over-the-Counter and Prescription Drug Products; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 1358d ago.

Organizations
1
Comments
2
RIN
Comment window
closed 1358d ago

Commenters (1)

View this docket on regulations.gov →

Attribution is name-based and imperfect. regulations.gov data is public record.